Articles on Antibody Drug Discovery

Antibody drug discovery is a critical focus in modern biotechnology, offering targeted solutions for complex diseases. This category explores the latest methodologies, emerging technologies, and key challenges in developing effective antibody-based therapeutics.

Featured Article

Immunotherapy Target: CD19 Antigen

CD19 remains a hot target in immunotherapy, driving innovation across a range of diseases. This is evidenced by recent approvals for new treatments in multiple sclerosis and leukemia and a major acquisition in the bispecific antibody space:

Browse articles by topic:

The New Frontier in SCLC Treatment: 4 Antigens Driving Antibody Innovation

The New Frontier in SCLC Treatment: 4 Antigens Driving Antibody Innovation

June 25, 2025

9 min read

STEAP1, the next blockbuster target for Prostate Cancer

STEAP1, the next blockbuster target for Prostate Cancer

June 16, 2025

5 min read

Targeted Therapies for Inflammatory Bowel Disease (IBD)

Targeted Therapies for Inflammatory Bowel Disease (IBD)

May 28, 2025

6 min read

The Landscape of GPCR-targeting Antibody Drug Development

The Landscape of GPCR-targeting Antibody Drug Development

May 9, 2025

9 min read

For Better Symptom Relief: Targeted Therapy for Asthma

For Better Symptom Relief: Targeted Therapy for Asthma

April 15, 2025

11 min read

At the Crossroads of Metabolic and Cancer Therapeutics — GDF15

At the Crossroads of Metabolic and Cancer Therapeutics — GDF15

April 1, 2025

7 min read

NPR1: Major Drug Target for Heart Failure

NPR1: Major Drug Target for Heart Failure

February 25, 2025

5 min read

Immunotherapy Target: CD19 Antigen

Immunotherapy Target: CD19 Antigen

February 4, 2025

7 min read

Case Review: Exploring domain proteins in antibody development

Case Review: Exploring domain proteins in antibody development

January 22, 2025

8 min read

GDF-8 (Myostatin) antibody Apitegromab achieves success in Phase III clinical trial

GDF-8 (Myostatin) antibody Apitegromab achieves success in Phase III clinical trial

June 13, 2024

4 min read

MSLN Targeted Drugs Entering the Fast Lane

MSLN Targeted Drugs Entering the Fast Lane

February 29, 2024

5 min read

New target for colorectal cancer: GPA33

New target for colorectal cancer: GPA33

February 24, 2023

4 min read

1 2 →

The New Frontier in SCLC Treatment: 4 Antigens Driving Antibody Innovation

The New Frontier in SCLC Treatment: 4 Antigens Driving Antibody Innovation

June 25, 2025

9 min read

STEAP1, the next blockbuster target for Prostate Cancer

STEAP1, the next blockbuster target for Prostate Cancer

June 16, 2025

5 min read

Targeted Therapies for Inflammatory Bowel Disease (IBD)

Targeted Therapies for Inflammatory Bowel Disease (IBD)

May 28, 2025

6 min read

The Landscape of GPCR-targeting Antibody Drug Development

The Landscape of GPCR-targeting Antibody Drug Development

May 9, 2025

9 min read

For Better Symptom Relief: Targeted Therapy for Asthma

For Better Symptom Relief: Targeted Therapy for Asthma

April 15, 2025

11 min read

At the Crossroads of Metabolic and Cancer Therapeutics — GDF15

At the Crossroads of Metabolic and Cancer Therapeutics — GDF15

April 1, 2025

7 min read

NPR1: Major Drug Target for Heart Failure

NPR1: Major Drug Target for Heart Failure

February 25, 2025

5 min read

Immunotherapy Target: CD19 Antigen

Immunotherapy Target: CD19 Antigen

February 4, 2025

7 min read

Case Review: Exploring domain proteins in antibody development

Case Review: Exploring domain proteins in antibody development

January 22, 2025

8 min read

GDF-8 (Myostatin) antibody Apitegromab achieves success in Phase III clinical trial

GDF-8 (Myostatin) antibody Apitegromab achieves success in Phase III clinical trial

June 13, 2024

4 min read

MSLN Targeted Drugs Entering the Fast Lane

MSLN Targeted Drugs Entering the Fast Lane

February 29, 2024

5 min read

New target for colorectal cancer: GPA33

New target for colorectal cancer: GPA33

February 24, 2023

4 min read

1 2 →

The Rise of Allogeneic Cell Therapies: Strategies, Challenges, and Clinical Advances

The Rise of Allogeneic Cell Therapies: Strategies, Challenges, and Clinical Advances

April 8, 2025

7 min read

CDH17: A Safe CAR-T Target for Treatment of Solid Tumors

CDH17: A Safe CAR-T Target for Treatment of Solid Tumors

July 19, 2022

5 min read

MRGPRX2: A Promising Target for Antibody Discovery in Allergy and Pain Disorders

MRGPRX2: A Promising Target for Antibody Discovery in Allergy and Pain Disorders

October 28, 2024

6 min read

GPCRs for Drug Discovery and Development

GPCRs for Drug Discovery and Development

September 20, 2023

2 min read

TM4SF1 in Cancer Immunotherapy: Emerging Research and Clinical Potential

TM4SF1 in Cancer Immunotherapy: Emerging Research and Clinical Potential

September 5, 2022

5 min read

Beyond GLP-1: ALK7–Activin E as a More Targeted Approach to Obesity Therapy

Beyond GLP-1: ALK7–Activin E as a More Targeted Approach to Obesity Therapy

December 15, 2025

7 min read

GDF-8: A New Era in Muscle Growth Therapies is Coming to Market

GDF-8: A New Era in Muscle Growth Therapies is Coming to Market

December 9, 2025

4 min read

KLK2: The New Promising Target for Prostate Cancer

KLK2: The New Promising Target for Prostate Cancer

December 4, 2025

4 min read

CDCP1: A New Therapeutic Target for Malignant Tumors

CDCP1: A New Therapeutic Target for Malignant Tumors

November 26, 2025

6 min read

IgE: The Key Therapeutic Target for Allergy Treatment

IgE: The Key Therapeutic Target for Allergy Treatment

November 20, 2025

7 min read

CDH17: The Next Breakthrough in Gastrointestinal Cancer Therapy

CDH17: The Next Breakthrough in Gastrointestinal Cancer Therapy

November 12, 2025

7 min read

FcRh5: An Emerging Therapeutic Target in Multiple Myeloma

FcRh5: An Emerging Therapeutic Target in Multiple Myeloma

October 22, 2025

7 min read

BAFF and APRIL: Key Targets in Autoimmune Diseases and a Review of Dual- and Single-Target Inhibitors

BAFF and APRIL: Key Targets in Autoimmune Diseases and a Review of Dual- and Single-Target Inhibitors

August 13, 2025

8 min read

A New Era in Targeted Therapies: Ichnos Glenmark Innovation and AbbVie Blaze a Trail with Tri-specific Antibodies

A New Era in Targeted Therapies: Ichnos Glenmark Innovation and AbbVie Blaze a Trail with Tri-specific Antibodies

July 29, 2025

3 min read

KACTUS Unveils Ultra-low Endotoxin Recombinant Protein Line — Powering Cleaner, Faster, Smarter Drug Discovery

KACTUS Unveils Ultra-low Endotoxin Recombinant Protein Line — Powering Cleaner, Faster, Smarter Drug Discovery

July 10, 2025

1 min read

Why Endotoxin Testing Matters: Safeguarding Recombinant Protein Applications in Immunology and Drug Discovery

Why Endotoxin Testing Matters: Safeguarding Recombinant Protein Applications in Immunology and Drug Discovery

May 22, 2025

4 min read

MASP2 Antibody Successful in Phase III Clinical Trial

MASP2 Antibody Successful in Phase III Clinical Trial

February 10, 2025

5 min read

1 2 3 →

Nanodiscs: A Versatile Platform for Membrane Protein Research

Nanodiscs: A Versatile Platform for Membrane Protein Research

April 28, 2025

8 min read

Addressing Challenging Antibody Discovery Targets with Virus-like Particle (VLP) Transmembrane Proteins

Addressing Challenging Antibody Discovery Targets with Virus-like Particle (VLP) Transmembrane Proteins

October 2, 2024

5 min read

Virus-like Particles: What they are and what they can o in Antibody Discovery

Virus-like Particles: What they are and what they can o in Antibody Discovery

August 28, 2024

6 min read

Rewriting Life's Code: CRISPR Precisely Edits Blood Disorder Defects

Rewriting Life's Code: CRISPR Precisely Edits Blood Disorder Defects

August 5, 2025

3 min read

AAV Capsid Optimization and Precision Quantification: Customized AAV ELISA Detection Solutions

AAV Capsid Optimization and Precision Quantification: Customized AAV ELISA Detection Solutions

June 4, 2025

2 min read

Ensuring Safe and Effective Gene Therapy with Precise AAV Capsid Quantification

Ensuring Safe and Effective Gene Therapy with Precise AAV Capsid Quantification

March 25, 2025

6 min read

Breaking News: KACTUS GMP-Grade Cas9 Powers Bioheng’s Breakthrough IND Clearance for Next-Gen UCAR-T Therapy

Breaking News: KACTUS GMP-Grade Cas9 Powers Bioheng’s Breakthrough IND Clearance for Next-Gen UCAR-T Therapy

March 5, 2025

4 min read

Effective Serratia marcescens Nuclease for DNA & RNA Removal: MaxNuclease™

Effective Serratia marcescens Nuclease for DNA & RNA Removal: MaxNuclease™

February 21, 2025

3 min read

Panorama of CRISPR Gene Editing Clinical Applications: 2024 Review

Panorama of CRISPR Gene Editing Clinical Applications: 2024 Review

January 31, 2025

8 min read

NK Cell Therapy Gets IND FDA Clearance with AccuBase® Base Editor from KACTUS

NK Cell Therapy Gets IND FDA Clearance with AccuBase® Base Editor from KACTUS

November 21, 2024

5 min read

2024 Milestones in CRISPR Clinical Pipelines

2024 Milestones in CRISPR Clinical Pipelines

November 11, 2024

5 min read

Base Editing vs. CRISPR: Navigating Precision Gene Therapy

Base Editing vs. CRISPR: Navigating Precision Gene Therapy

October 14, 2024

5 min read

AccuBase™ Base Editor Continues to Advance NK Cell Therapies

AccuBase™ Base Editor Continues to Advance NK Cell Therapies

July 31, 2024

4 min read

IND Approval for Solid Tumor Therapy Using KACTUS Cas9 Enzyme

IND Approval for Solid Tumor Therapy Using KACTUS Cas9 Enzyme

July 24, 2024

4 min read

Gene Editing Drugs from the EMA Review Perspective

Gene Editing Drugs from the EMA Review Perspective

June 25, 2024

5 min read

1 2 →

The History of Refolding MHCs: Building MHC Molecules from the Ground Up

The History of Refolding MHCs: Building MHC Molecules from the Ground Up

October 6, 2025

5 min read

Expanding Landscape of TCR Therapies: Clinical Breakthroughs, Formats, and Production Support

Expanding Landscape of TCR Therapies: Clinical Breakthroughs, Formats, and Production Support

June 12, 2025

5 min read

Cracking KRAS: How TCR-T and TCR-Mimic Antibodies Are Changing KRAS Mutant Cancers

Cracking KRAS: How TCR-T and TCR-Mimic Antibodies Are Changing KRAS Mutant Cancers

March 18, 2025

10 min read

Rethinking Refolding: The Case for Mammalian-Expressed Single-Chain Trimer MHCs

Rethinking Refolding: The Case for Mammalian-Expressed Single-Chain Trimer MHCs

September 18, 2024

5 min read

Neoantigen-Based Immunotherapy: Unveiling Disease-Specific Targets

Neoantigen-Based Immunotherapy: Unveiling Disease-Specific Targets

August 20, 2024

4 min read

Butyrophilin (BTN) family: γδ T Cell Receptor Ligands, Immunomodulators and More

Butyrophilin (BTN) family: γδ T Cell Receptor Ligands, Immunomodulators and More

December 27, 2023

5 min read

Webinar: Transforming Tumor Research: Engineering MHCs as Versatile Reagents

Webinar: Transforming Tumor Research: Engineering MHCs as Versatile Reagents

December 20, 2023

Transforming Tumor Research: Engineering MHCs as Versatile Reagents

Transforming Tumor Research: Engineering MHCs as Versatile Reagents

September 7, 2023

1 min read

Cell and Antibody Therapies Targeting HLA-G

Cell and Antibody Therapies Targeting HLA-G

February 14, 2023

3 min read

TCR Therapy Targeting MAGE-A4

TCR Therapy Targeting MAGE-A4

January 2, 2023

1 min read

Have questions? Get in touch!

support@kactusbio.us

Antibody Drug Discovery Insights & Trends

↑